Krispy Kreme will give you a free doughnut in August—if you’re wearing the right shoes

David Ellison, the son of billionaire Larry Ellison, is making waves in Hollywood—but is his success truly his own? This piece digs into whether his rising net worth and industry clout (think Skydance Media’s blockbuster deals) are the result of his hustle or just a silver-spoon advantage. The article doesn’t shy away from the debate, weighing his legit achievements (like producing major films) against the undeniable head start his family name provided.

Editor’s Note: It’s the classic "nepo baby" question, but with real stakes. Ellison’s trajectory isn’t just gossip—it reflects bigger conversations about privilege in Hollywood and whether legacy overshadows merit. For readers, it’s either a relatable critique of inequality or a vindication of hard work, depending on where you stand. Either way, it’s a snapshot of how power (and money) really moves in entertainment.

A healthcare AI startup called OpenEvidence, founded by billionaire Daniel Nadler, just hit a whopping $3.5 billion valuation. The company’s tech helps doctors and researchers sift through medical data faster—think of it as a supercharged assistant for diagnosing and treating patients. While the exact details of their funding or growth aren’t spelled out here, that price tag alone signals big confidence in AI’s role in medicine.

Editor’s Note: This isn’t just another tech unicorn story. OpenEvidence’s valuation hints at how seriously investors are betting on AI to transform healthcare—whether by speeding up diagnoses, cutting costs, or improving accuracy. For patients, that could eventually mean better care, but it also raises questions about who profits and how these tools get used in real hospitals. Worth keeping an eye on.

Procept Biorobotics, a medical robotics company, saw its stock price drop after revealing a CEO transition plan. Investors seem wary of the leadership change, even though the company hasn’t disclosed any underlying issues. The market reaction suggests uncertainty about whether the new CEO can maintain the company’s trajectory.

Editor’s Note: CEO transitions can rattle investors, especially in tech-driven sectors like robotics where leadership vision is crucial. The dip doesn’t necessarily signal trouble—it might just be short-term jitters—but it shows how sensitive markets are to executive shuffles. If the new leader has big shoes to fill, Procept will need to reassure shareholders fast.

CBRE Group, the global commercial real estate giant, just saw its stock price soar to a record high of $147.76—a clear sign investors are betting big on its growth. This milestone reflects strong market confidence, likely fueled by solid earnings, strategic expansions, or a booming real estate sector.

Editor’s Note: When a heavyweight like CBRE hits an all-time high, it’s not just a win for shareholders—it’s a pulse check on the broader real estate market. If commercial property demand is driving this surge, it could hint at economic resilience or shifting trends in how businesses invest in space. Either way, it’s a story worth watching, especially for anyone with skin in the real estate or financial game.

Luxury giant LVMH is reportedly in discussions to sell off the Marc Jacobs brand, according to The Wall Street Journal. While details are still emerging, this could signal a strategic shift for LVMH as it refines its portfolio of high-end labels.

Editor’s Note: Marc Jacobs has been a staple in LVMH’s lineup since the late '90s, so a potential sale raises questions—is LVMH streamlining, or does Jacobs need fresh ownership to thrive? For fashion watchers, it’s a juicy shake-up in the luxury world, hinting at bigger moves ahead.